AstraZeneca Drug Tezspire Clears Phase III Trial for Esophagitis Treatment

AstraZeneca announced that its investigational therapy Tezspire successfully achieved its primary objectives in a Phase III clinical trial for eosinophilic esophagitis. The positive results pave the way for potential regulatory approval and expanded treatment options for patients with this rare inflammatory condition.